Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 56(18): 7396-415, 2013 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-23968485

RESUMO

There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase-topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K(+) channel block. On the other hand, analog 49e displayed lower hERG K(+) channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.


Assuntos
Antibacterianos/síntese química , Antibacterianos/farmacologia , DNA Topoisomerases/metabolismo , Desenho de Fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Piranos/síntese química , Piranos/farmacologia , Animais , Antibacterianos/metabolismo , Antibacterianos/farmacocinética , Técnicas de Química Sintética , DNA Girase/química , DNA Girase/metabolismo , DNA Topoisomerase IV/antagonistas & inibidores , DNA Topoisomerase IV/química , DNA Topoisomerase IV/metabolismo , DNA Topoisomerases/química , Feminino , Bactérias Gram-Positivas/enzimologia , Humanos , Concentração Inibidora 50 , Camundongos , Simulação de Acoplamento Molecular , Conformação Proteica , Piranos/metabolismo , Piranos/farmacocinética , Ratos , Relação Estrutura-Atividade , Inibidores da Topoisomerase II , Inibidores da Topoisomerase/síntese química , Inibidores da Topoisomerase/metabolismo , Inibidores da Topoisomerase/farmacocinética , Inibidores da Topoisomerase/farmacologia
2.
Bioorg Med Chem Lett ; 22(21): 6705-11, 2012 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-23006603

RESUMO

A series of 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) with potent inhibition of bacterial NAD(+)-dependent DNA ligases (LigAs) evolved from a 2,4-diaminopteridine derivative discovered by HTS. The design was guided by several highly resolved X-ray structures of our inhibitors in complex with either Streptococcus pneumoniae or Escherichia coli LigA. The structure-activity-relationship based on the ANC scaffold is discussed. The in-depth characterization of 2-amino-6-bromo-7-(trifluoromethyl)-[1,8]-naphthyridine-3-carboxamide, which displayed promising in vitro (MIC Staphylococcus aureus 1 mg/L) and in vivo anti-staphylococcal activity, is presented.


Assuntos
Antibacterianos/síntese química , Antibacterianos/farmacologia , DNA Ligases/antagonistas & inibidores , Desenho de Fármacos , Staphylococcus/efeitos dos fármacos , Animais , Antibacterianos/química , Antibacterianos/uso terapêutico , Cristalografia por Raios X , DNA Bacteriano/antagonistas & inibidores , Concentração Inibidora 50 , Camundongos , Testes de Sensibilidade Microbiana , Estrutura Molecular , Ratos , Infecções Estafilocócicas/tratamento farmacológico , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...